Intermitted Treatment

The present invention provides the use of a bone antiresorptive compound for the manufacture of a pharmaceutical composition for a bone metabolism marker monitored bone mass augmenting therapy, characterized in that the bone mass augmenting therapy is a bone anabolic therapy, which is defined by an increase of mineralized bone volume, and the pharmaceutical composition is for intermittent administration starting with an administration of the pharmaceutical composition and at least one successive administration, wherein the successive administration is performed after an increase of the bone metabolism marker by at least 10%.

• Zentrum für Biologische Wissenschaften